Key facts

Below are highlights of our performance over the last 12 months:

January 2016

Corvus announced as adenosine receptor antagonist licensee (deal previously announced in February 2015)

April 2016

Successful completion of CCP-08 pivotal single-dose comparative bioavailability study  

April 2016

Successful completion of CCP-07 pivotal multiple-dose comparative bioavailability study

May 2016

Successfully raised £40m (before expenses) in Placing through issue of 80m new Ordinary Shares at a Placing Price of 50p per share

May 2016

Suir Pharma, sole supplier for Moxatag® placed in provisional liquidation

July 2016

€500k milestone received following achievement of new milestone in first oncology drug discovery collaboration with Servier

July 2016

Successful completion of CCP-08 pivotal multiple-dose comparative bioavailability study

September 2016

FDA accepted CCP-07 for full review, with PDUFA date of 20 April 2017

December 2016

FDA accepted CCP-08 for full review, with PDUFA date of 4 August 2017

February 2017

$3m milestone received following achievement of a clinical milestone from collaboration with Corvus

March 2017

New two-year oncology drug discovery collaboration on undisclosed target entered with Servier, strengthening existing partnership

April 2016

Successful completion of CCP-08 pivotal single-dose comparative bioavailability study  

April 2016

Successful completion of CCP-07 pivotal multiple-dose comparative bioavailability study

May 2016

Successfully raised £40m (before expenses) in Placing through issue of 80m new Ordinary Shares at a Placing Price of 50p per share

May 2016

Suir Pharma, sole supplier for Moxatag® placed in provisional liquidation

July 2016

€500k milestone received following achievement of new milestone in first oncology drug discovery collaboration with Servier

July 2016

Successful completion of CCP-08 pivotal multiple-dose comparative bioavailability study

Sept 2016

FDA accepted CCP-07 for full review, with PDUFA date of 20 April 2017

Dec 2016

FDA accepted CCP-08 for full review, with PDUFA date of 4 August 2017

Feb 2017

$3m milestone received following achievement of a clinical milestone from its collaboration with Corvus

Mar 2017

New two-year oncology drug discovery collaboration on undisclosed target entered with Servier, strengthening existing partnership

Latest News

Servier and Vernalis plc announce achievement of 3 milestones in their oncology drug discovery collaboration

Servier and Vernalis plc are pleased to announce the achievement of two research milestones and one clinical milestone in their oncology drug discovery collaboration, triggering a total payment of €2 million to Vernalis.

 

Read more ...

At a glance

More information on Vernalis and its pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch